Clinical and immunological characteristics of 69 leukocyte adhesion deficiency-I patients.
CD11a
CD18
leukocyte adhesion deficiency type 1
novel mutation
primary immunodeficiency
Journal
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
ISSN: 1399-3038
Titre abrégé: Pediatr Allergy Immunol
Pays: England
ID NLM: 9106718
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
14
06
2023
received:
06
02
2023
accepted:
20
06
2023
medline:
27
7
2023
pubmed:
26
7
2023
entrez:
26
7
2023
Statut:
ppublish
Résumé
In order to support the comprehensive classification of Leukocyte Adhesion Deficiency-I (LAD-I) severity by simultaneous screening of CD11a/CD18, this study assessed clinical, laboratory, and genetic findings along with outcomes of 69 LAD-I patients during the last 15 years. Sixty-nine patients (40 females and 29 males) with a clinical phenotype suspected of LAD-I were referred to Immunology, Asthma, and Allergy research institute, Tehran, Iran between 2007 and 2022 for further advanced immunological screening and genetic evaluations as well as treatment, were enrolled in this study. The diagnosis median age of the patients was 6 months. Delayed umbilical cord separation was found in 25 patients (36.2%). The median diagnostic delay time was 4 months (min-max: 0-82 months). Forty-six patients (66.7%) were categorized as severe (CD18 and/or CD11a: below 2%); while 23 children (33.3%) were in moderate category (CD18 and/or CD11a: 2%-30%). During the follow-ups, 55.1% of children were alive with a mortality rate of 44.9%. Skin ulcers (75.4%), omphalitis (65.2%), and gingivitis (37.7%) were the most frequent complaints. Genetic analysis of the patients revealed 14 previously reported and three novel pathogenic mutations in the ITGB2 gene. The overall survival of patients with and without hematopoietic stem cell transplantation was 79.3% and 55.6%, respectively. Physicians' awareness of LAD-I considering delayed separation of umbilical cord marked neutrophilic leukocytosis, and variability in CD11 and CD18 expression levels, and genetic analysis leads to early diagnosis and defining disease severity. Moreover, the prenatal diagnosis would benefit families with a history of LAD-I.
Sections du résumé
BACKGROUND
In order to support the comprehensive classification of Leukocyte Adhesion Deficiency-I (LAD-I) severity by simultaneous screening of CD11a/CD18, this study assessed clinical, laboratory, and genetic findings along with outcomes of 69 LAD-I patients during the last 15 years.
METHODS
Sixty-nine patients (40 females and 29 males) with a clinical phenotype suspected of LAD-I were referred to Immunology, Asthma, and Allergy research institute, Tehran, Iran between 2007 and 2022 for further advanced immunological screening and genetic evaluations as well as treatment, were enrolled in this study.
RESULTS
The diagnosis median age of the patients was 6 months. Delayed umbilical cord separation was found in 25 patients (36.2%). The median diagnostic delay time was 4 months (min-max: 0-82 months). Forty-six patients (66.7%) were categorized as severe (CD18 and/or CD11a: below 2%); while 23 children (33.3%) were in moderate category (CD18 and/or CD11a: 2%-30%). During the follow-ups, 55.1% of children were alive with a mortality rate of 44.9%. Skin ulcers (75.4%), omphalitis (65.2%), and gingivitis (37.7%) were the most frequent complaints. Genetic analysis of the patients revealed 14 previously reported and three novel pathogenic mutations in the ITGB2 gene. The overall survival of patients with and without hematopoietic stem cell transplantation was 79.3% and 55.6%, respectively.
CONCLUSION
Physicians' awareness of LAD-I considering delayed separation of umbilical cord marked neutrophilic leukocytosis, and variability in CD11 and CD18 expression levels, and genetic analysis leads to early diagnosis and defining disease severity. Moreover, the prenatal diagnosis would benefit families with a history of LAD-I.
Substances chimiques
CD18 Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13990Informations de copyright
© 2023 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
van de Vijver E, van den Berg TK, Kuijpers TW. Leukocyte adhesion deficiencies. Hematol Oncol Clin North Am. 2013;27(1):101-116, viii.
Justiz Vaillant AA, Ahmad F. Leukocyte adhesion deficiency. In: StatPearls. StatPearls Publishing LLC; 2022.
Wolach B, Gavrieli R, Wolach O, et al. Leucocyte adhesion deficiency-a multicentre national experience. Eur J Clin Invest. 2019;49(2):e13047.
Almarza Novoa E, Kasbekar S, Thrasher AJ, et al. Leukocyte adhesion deficiency-I: a comprehensive review of all published cases. J Allergy Clin Immunol Pract. 2018;6:1418-1420.e10.
Hamidieh AA, Pourpak Z, Alimoghaddam K, et al. Successful allogeneic stem cell transplantation with a reduced-intensity conditioning in a leukocyte adhesion deficiency type I patient. Pediatr Transplant. 2011;15(2):E30-E33.
Jabbari Azad F, Ardalan M, Hoseinpoor Rafati A, Sotoudeh S, Pourpak Z. Osteomyelitis in leukocyte adhesion deficiency type 1 syndrome. J Infect Dev Ctries. 2010;4(3):175-178.
Movahedi M, Entezari N, Pourpak Z, et al. Clinical and laboratory findings in Iranian patients with leukocyte adhesion deficiency (study of 15 cases). J Clin Immunol. 2007;27(3):302-307.
van de Vijver E, Maddalena A, Sanal O, et al. Hematologically important mutations: leukocyte adhesion deficiency (first update). Blood Cells Mol Dis. 2012;48(1):53-61.
Fagerholm SC, Guenther C, Llort Asens M, Savinko T, Uotila LM. Beta2-Integrins and interacting proteins in leukocyte trafficking, immune suppression, and immunodeficiency disease. Front Immunol. 2019;10:254.
Bednarczyk M, Stege H, Grabbe S, Bros M. β2 Integrins-multi-functional leukocyte receptors in health and disease. Int J Mol Sci. 2020;21(4):1402.
Campbell ID, Humphries MJ. Integrin structure, activation, and interactions. Cold Spring Harb Perspect Biol. 2011;3(3):a004994.
Tan SM. The leucocyte beta2 (CD18) integrins: the structure, functional regulation and signalling properties. Biosci Rep. 2012;32(3):241-269.
Bouti P, Webbers SDS, Fagerholm SC, et al. β2 integrin signaling cascade in neutrophils: more than a single function. Front Immunol. 2020;11:619925.
Levy-Mendelovich S, Rechavi E, Abuzaitoun O, et al. Highlighting the problematic reliance on CD18 for diagnosing leukocyte adhesion deficiency type 1. Immunol Res. 2016;64(2):476-482.
Horikoshi Y, Umeda K, Imai K, et al. Allogeneic hematopoietic stem cell transplantation for leukocyte adhesion deficiency. J Pediatr Hematol Oncol. 2018;40(2):137-140.
Etzioni A. Defects in the leukocyte adhesion cascade. Clin Rev Allergy Immunol. 2010;38(1):54-60.
Taghizade Mortezaee F, Esmaeli B, Badalzadeh M, et al. Investigation of ITGB2 gene in 12 new cases of leukocyte adhesion deficiency-type I revealed four novel mutations from Iran. Arch Iran Med. 2015;18(11):760-764.
Hamidieh AA, Pourpak Z, Hosseinzadeh M, et al. Reduced-intensity conditioning hematopoietic SCT for pediatric patients with LAD-1: clinical efficacy and importance of chimerism. Bone Marrow Transplant. 2012;47(5):646-650.
Hamidieh AA, Behfar M, Pourpak Z, et al. Long-term outcomes of fludarabine, melphalan and antithymocyte globulin as reduced-intensity conditioning regimen for allogeneic hematopoietic stem cell transplantation in children with primary immunodeficiency disorders: a prospective single center study. Bone Marrow Transplant. 2016;51(2):219-226.
Oudesluys-Murphy AM, Eilers GA, de Groot CJ. The time of separation of the umbilical cord. Eur J Pediatr. 1987;146(4):387-389.
Parvaneh N, Mamishi S, Rezaei A, et al. Characterization of 11 new cases of leukocyte adhesion deficiency type 1 with seven novel mutations in the ITGB2 gene. J Clin Immunol. 2010;30(5):756-760.
Matsuura S, Kishi F, Tsukahara M, et al. Leukocyte adhesion deficiency: identification of novel mutations in two Japanese patients with a severe form. Biochem Biophys Res Commun. 1992;184(3):1460-1467.
Shaw JM, Al-Shamkhani A, Boxer LA, et al. Characterization of four CD18 mutants in leucocyte adhesion deficient (LAD) patients with differential capacities to support expression and function of the CD11/CD18 integrins LFA-1, Mac-1 and p150, 95. Clin Exp Immunol. 2001;126(2):311-318.
Arnaout MA, Dana N, Gupta SK, Tenen DG, Fathallah DM. Point mutations impairing cell surface expression of the common beta subunit (CD18) in a patient with leukocyte adhesion molecule (Leu-CAM) deficiency. J Clin Invest. 1990;85(3):977-981.
Teimourian S, De Boer M, Roos D, et al. Genetic analysis of 13 iranian families with leukocyte adhesion deficiency type 1. J Pediatr Hematol Oncol. 2019;41(1):e3-e6.
Esmaeili B, Ghadami M, Fazlollahi MR, et al. Prenatal diagnosis of leukocyte adhesion deficiency type-1 (five cases from Iran with two new mutations). Iran J Allergy Asthma Immunol. 2014;13(1):61-65.
Back AL, Kerkering M, Baker D, Bauer TR, Embree LJ, Hickstein DD. A point mutation associated with leukocyte adhesion deficiency type 1 of moderate severity. Biochem Biophys Res Commun. 1993;193(3):912-918.
Rezaei N, Pourpak Z, Aghamohammadi A, et al. Consanguinity in primary immunodeficiency disorders; the report from Iranian Primary Immunodeficiency Registry. Am J Reprod Immunol. 2006;56(2):145-151.
Hosseini-Chavoshi M, Abbasi-Shavazi MJ, Bittles AH. Consanguineous marriage, reproductive behaviour and postnatal mortality in contemporary Iran. Hum Hered. 2014;77(1-4):16-25.
Roos D, van Leeuwen K, Madkaikar M, et al. Hematologically important mutations: leukocyte adhesion deficiency (second update). Blood Cells Mol Dis. 2023;99:102726.
Guan S, Tan SM, Li Y, et al. Characterization of single amino acid substitutions in the beta2 integrin subunit of patients with leukocyte adhesion deficiency (LAD)-1. Blood Cells Mol Dis. 2015;54(2):177-182.
Madkaikar M, Italia K, Gupta M, et al. Molecular characterization of leukocyte adhesion deficiency-I in Indian patients: identification of 9 novel mutations. Blood Cells Mol Dis. 2015;54(3):217-223.
Thakur N, Sodani R, Chandra J, Singh V. Leukocyte adhesion defect type 1 presenting with recurrent pyoderma gangrenosum. Indian J Dermatol. 2013;58(2):158.
Madkaikar M, Italia K, Gupta M, et al. Leukocyte adhesion deficiency-I with a novel intronic mutation presenting with pyoderma gangrenosum- like lesions. J Clin Immunol. 2015;35(4):431-434.
Bakhtiar S, Salzmann-Manrique E, Blok HJ, et al. Allogeneic hematopoietic stem cell transplantation in leukocyte adhesion deficiency type I and III. Blood Adv. 2021;5(1):262-273.
Cabanillas D, Regairaz L, Deswarte C, et al. Leukocyte adhesion deficiency type 1 (LAD1) with expressed but nonfunctional CD11/CD18. J Clin Immunol. 2016;36(7):627-630.
Fischer A, Lisowska-Grospierre B, Anderson DC, Springer TA. Leukocyte adhesion deficiency: molecular basis and functional consequences. Immunodefic Rev. 1988;1(1):39-54.
Celiksoy MH, Köker MY, Gezdirici A, Ozsoy S, Malbora B, Gungor S. A novel ITGB2 variant with long survival in patients with leukocyte adhesion defect type-I. Immunol Res. 2021;69(5):461-466.